Pancreatic Cancer

>

Latest News

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

July 25th 2025

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

July 25th 2025

Quemliclustat plus gemcitabine and nab-paclitaxel chemotherapy outperformed median OS benchmarks in patients with metastatic PDAC.
FDA Grants Orphan Drug Designation to Quemliclustat in Pancreatic Cancer

July 12th 2025

Explore the latest advancements in pancreatic cancer treatment, focusing on genetic mutations, targeted therapies, and emerging clinical strategies.
3 Things You Should Know About Targeting NRG1 and Rare Drivers in Pancreatic Cancer

July 2nd 2025

Findings from the phase 2b ASCEND trial will be presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress on July 2, 2025.
Certepetide Displays Positive Efficacy Trend in Metastatic PDAC

June 27th 2025

Latest CME Events & Activities

More News